Alnylam Pharmaceuticals - Stock Price History | ALNY

Historical daily share price chart and data for Alnylam Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Alnylam Pharmaceuticals as of September 27, 2021 is 193.85.
  • The all-time high Alnylam Pharmaceuticals stock closing price was 207.73 on August 10, 2021.
  • The Alnylam Pharmaceuticals 52-week high stock price is 209.72, which is 8.2% above the current share price.
  • The Alnylam Pharmaceuticals 52-week low stock price is 119.29, which is 38.5% below the current share price.
  • The average Alnylam Pharmaceuticals stock price for the last 52 weeks is 154.24.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Alnylam Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 131.5823 115.6200 165.4900 93.1200 129.9700 12.85%
2019 84.8380 72.7600 124.2300 65.8600 115.1700 57.96%
2018 101.1745 131.8500 148.5400 62.6700 72.9100 -42.61%
2017 80.4191 38.6400 139.9800 36.8800 127.0500 239.34%
2016 60.4803 93.0300 94.7700 31.4100 37.4400 -60.23%
2015 106.1699 97.7700 138.7300 75.0200 94.1400 -2.95%
2014 73.5115 63.8600 106.5900 48.8700 97.0000 50.86%
2013 40.1254 19.1700 66.9100 18.7300 64.3000 252.33%
2012 14.3445 8.6600 20.9900 8.6500 18.2500 123.93%
2011 8.7621 10.0100 11.3700 6.0000 8.1500 -17.34%
2010 14.9240 18.1400 18.7200 8.9600 9.8600 -44.04%
2009 20.1578 25.1500 25.9400 15.1400 17.6200 -28.75%
2008 27.1632 28.9200 35.9500 17.2900 24.7300 -14.96%
2007 23.7309 21.5700 36.5500 15.1600 29.0800 35.89%
2006 15.6638 12.9600 23.8100 11.6100 21.4000 60.18%
2005 9.2154 7.5800 14.1900 6.9000 13.3600 78.85%
2004 6.1401 7.0000 8.2600 3.9500 7.4700 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $23.039B $0.493B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29